Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26501738 | 0.86 | TAAR1 (0.37) | ALDH1A1HPGDLMNAL3MBTL1KDM4E | |
| SCHEMBL26501733 | 0.86 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1HPGDLMNA | |
| SCHEMBL26501716 | 0.83 | ABCB11 (0.32) | ABCB11KMT2AESR1ESR2 | |
| SCHEMBL26501736 | 0.82 | ALDH1A1 (0.37) | ALDH1A1HPGDLMNAL3MBTL1KDM4E | |
| SCHEMBL26501737 | 0.82 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1HPGDLMNA | |
| SCHEMBL26501655 | 0.74 | DHFR (0.35) | ALDH1A1ABCB11KMT2AMEN1LMNA | |
| SCHEMBL26501734 | 0.74 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1HPGDLMNA | |
| SCHEMBL29200077 | 0.74 | GAA (0.47) | ALDH1A1ABCB11KMT2AMEN1KDM4E | |
| SCHEMBL17720261 | 0.74 | GAA (0.47) | ALDH1A1ABCB11KMT2AMEN1KDM4E | |
| SCHEMBL26501795 | 0.74 | RAB9A (0.35) | ABCB11LMNAL3MBTL1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | ALDH1A1 715/4885ABCB11 872/4885KMT2A 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.